A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world. CONTACT: Amgen, Thousand Oaks Megan Fox, 805-447-1423 (media)Trish Rowland, 805-447-5631(media) Arvind Sood, 805-447-1060 (investors), Five Prime Media and Investor ContactMartin Forrest, 415-365-5625, View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash-301240358.html. Please note that the information you are about to view may not comply with Canadian regulatory requirements. For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. ", "This is an exciting day for patients who may one day benefit from the promise of bemaritizumab and our full pipeline. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. Amgen ist mit ca. Mehr erfahren. THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, … Reimbursement Support Services and Financial Assistance Programs. This is your opportunity to Live, Win, and Thrive with a world-renowned organization. Folgen Sie uns auf Twitter. About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Bei den Einzelthemen geht es heute um Amgen, Beigene, AMD, Twitter, K+S, Thyssenkrupp, Zalando und Grenke. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. About Gastric Cancer and GEJ CancerGastric cancer, also known as stomach cancer, is the third most common cause of cancer death worldwide and, excluding non-melanoma skin cancer, the fifth most common cancer worldwide, with over 1,000,000 new cases diagnosed each year.2 For HER2 negative patients, frontline therapy available today is the same systemic chemotherapy available since the 1990s.3,4. This is your opportunity to Live, Win, and Thrive with a world-renowned organization. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. Patient Assistance For reimbursement options and information on help paying for Amgen medications in the U.S., healthcare professionals and patients can also visit the Reimbursement Support Services and Financial Assistance Programs page . Updated April 21, 2020. Five Prime's lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer. By their nature, forward-looking statements involve risks and uncertainty because they relate to events and depend on circumstances that will occur in the future, and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. MedInfo-Hotline Tel. Neither can there be any guarantee that such product will be successfully commercialized even if regulatory approvals are obtained. THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion.